November 12, 2020

To,

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
BSE Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Scrip Code: STAR

Dear Sirs,

Sub: Order of the National Company Law Tribunal, Mumbai Bench sanctioning merger of wholly owned subsidiaries

This has reference to our earlier communication of June 19, 2020 providing update on merger of Arrow Remedies Private Limited (“Arrow”), Fagris Medica Private Limited (“Fagris”) and Strides Emerging Markets Limited (“SEML”) with the Company, which are direct/indirect wholly-owned subsidiaries of the Company.

We wish to inform you that the Mumbai Bench of the Hon’ble National Company Law Tribunal (“NCLT”), vide its order dated November 6, 2020 (certified copy received on November 11, 2020) has sanctioned the joint petition filed by Arrow, Fagris and the Company (together referred to as “Petitioner Companies”) for approval of the Scheme of Amalgamation of Arrow, Fagris, and SEML with the Company and their respective shareholders and creditors (“Scheme”) pursuant to the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013.

The Appointed Date for the said merger is April 1, 2019.

Kindly note that, a petition for approval of the Scheme was also filed before the Bengaluru Bench of the Hon’ble NCLT, since the registered office of SEML is situated in Bengaluru, Karnataka. The Bengaluru Bench of the NCLT has already approved the Scheme, which was intimated to the Stock Exchanges vide our letter dated June 19, 2020.
The Scheme would be effective upon completion of all necessary post approval actions in accordance with the Scheme and orders passed by the Bengaluru Bench and the Mumbai Bench of the NCLT.

You are requested to take the same on record.

Thanks & Regards,
For Strides Pharma Science Limited,

Manjula Ramamurthy
Company Secretary